Aurinia Pharmaceuticals (AUPH) EBT (2019 - 2026)

Aurinia Pharmaceuticals' EBT history runs 8 years deep, the most recent figure standing at $43.9 million for Q1 2026.

• Quarterly EBT rose 80.4% year-over-year to $43.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.7 million (up 219.88% YoY) and the FY2025 annual result came in at $114.2 million, up 1432.72% from the prior year.
• EBT was $43.9 million for Q1 2026 at Aurinia Pharmaceuticals, up from $35.7 million in the prior quarter.
• Across five years, EBT topped out at $43.9 million in Q1 2026 and bottomed at -$37.6 million in Q1 2022.
• A 5-year average of -$1.1 million and a median of -$8.0 million in 2022 frame the typical range for EBT.
• Annual changes were most pronounced in 2023 — EBT plunged 63.65% — and 2025, when it soared 2942.63%.
• Aurinia Pharmaceuticals' EBT stood at -$25.2 million in 2022, then decreased by 4.86% to -$26.4 million in 2023, then jumped by 104.44% to $1.2 million in 2024, then surged by 2942.63% to $35.7 million in 2025, then advanced by 23.07% to $43.9 million in 2026.
• Business Quant data shows AUPH's EBT at $43.9 million in Q1 2026, $35.7 million in Q4 2025, and $32.0 million in Q3 2025.